First-line combination treatment for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of two drugs, anlotinib and benmelstobart, for people with advanced esophageal squamous cell carcinoma that has not been treated before or has come back after more than six months. The goal is to see if this combination can help control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of esophageal squamous cell carcinoma that is locally advanced, recurrent, or metastatic and cannot be removed by surgery.
- You must not have had any prior systemic treatment for this cancer, or if you had treatment, it must have been completed more than six months ago.
- You must be at least 18 years old and have a good performance status (ECOG 0-1), meaning you are fully active or restricted only in physically strenuous activity.
- Your tumor must have certain genetic changes (TP53 or FAT1 mutation, and no NOTCH3 mutation) that will be checked by the study team.
- You must have at least one measurable tumor that has not been previously treated with radiation, or if it was, it must have grown after that treatment.
- Your blood counts and organ function (liver, kidneys, thyroid) must be within acceptable levels as determined by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests penpulimab plus chemotherapy (with or without an added targeted pill called anlotinib) in people with advanced esophageal squamous cell carcinoma. It aims to slow tumor growth and improve outcomes, especially for patients who can’t have curative surgery or radiation.
This trial tests a new combination of two drugs (bempemab and anlotinib) as a first treatment for older adults with advanced lung cancer. The goal is to see if this drug pair can shrink tumors and slow the cancer, possibly without the need for chemo or radiation.
This trial tests a combination of three drugs—anlotinib, benmelstobart, and chemotherapy—as a first treatment for pancreatic cancer that has spread. The goal is to see if this combo can shrink tumors or slow the cancer's growth better than current options.
This trial tests a combination of two drugs (cadonilimab and anlotinib) followed by radiation therapy for esophageal cancer that has returned or spread. The goal is to see if this approach helps shrink tumors and control the disease.
This trial tests a combination of immunotherapy and a drug called anlotinib (which helps stop blood vessel growth to tumors) after surgery for esophageal cancer. If you had some cancer left after surgery and it spread to lymph nodes, this treatment might help prevent the cancer from coming back.
This trial tests a combination of two oral and infused drugs to slow or shrink advanced thyroid cancer that has stopped responding to initial treatment. It may offer a new option for people with limited choices.
Hear when a new Advanced Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.